Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma
| Autor: | Jonathan Baird-Gunning, Matteo S. Carlino, Yash Gawarikar, Matthew Silsby, Jessica Smith, Dinushi Weerasinghe, Steve Vucic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.drug_class
business.industry Melanoma medicine.medical_treatment Cancer Ipilimumab Immunotherapy Case Reports Monoclonal antibody medicine.disease 03 medical and health sciences 0302 clinical medicine Immune system 030220 oncology & carcinogenesis Cancer cell medicine Cancer research Neurology (clinical) Nivolumab business 030217 neurology & neurosurgery medicine.drug |
| Popis: | Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|